Literature DB >> 2985103

Effects of repeated doses of enalapril on renal function in man.

W R McNabb, F H Noormohamed, B A Brooks, A E Till, A F Lant.   

Abstract

Ten healthy subjects received 10 mg oral enalapril (MK 421) daily for a period of 8 days. Renal clearances of electrolytes, urate and phosphate were monitored and factored for glomerular filtration rate, as measured by creatinine clearance, with particular emphasis on the first and eighth day of treatment. Apart from a fall of around 10% in creatinine clearance between 1-2 h on both days 1 and 8, GFR remained unchanged throughout the study. Fractional sodium excretion increased in a biphasic manner by approximately 50% over control between 1-2 h and 4-8 h on day 1. Significant chloruresis (+39.0 +/- 12.9%) and kaluresis (+26.5 +/- 10.3%) occurred between 4-8 h. Urinary pH increased between 0-1 h (+0.29 +/- 0.12; P less than 0.05), and between 4-8 h (+0.50 +/- 0.08; P less than 0.01). The biphasic saluretic effect was also seen between 1-2 h and 4-8 h on day 8. Enalapril caused significant increases in urate and phosphate excretion on day 8 of therapy. There was a biphasic increase in fractional urate excretion at 1-2 h (+28.1 +/- 6.9%; P less than 0.05) and at 4-8 h (+21.0 +/- 6.0% P less than 0.01). Significant phosphaturia (+36.8 +/- 5.2%; P less than 0.05) was also observed at 4-8 h on day 8. Urinary drug excretion was also biphasic; over the first 2 h the predominant drug form was unchanged enalapril, whilst the peak excretion of the diacid metabolite, enalaprilat, occurred at 4-8 h.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2985103      PMCID: PMC1463726          DOI: 10.1111/j.1365-2125.1985.tb02654.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  26 in total

1.  Phosphate transport along the nephron.

Authors:  F G Knox; H Osswald; G R Marchand; W S Spielman; J A Haas; T Berndt; S P Youngberg
Journal:  Am J Physiol       Date:  1977-10

2.  Stimulation of renal sodium reabsorption by angiotensin II.

Authors:  M D Johnson; R L Malvin
Journal:  Am J Physiol       Date:  1977-04

3.  Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects.

Authors:  D B Brunner; G Desponds; J Biollaz; I Keller; F Ferber; H Gavras; H R Brunner; J L Schelling
Journal:  Br J Clin Pharmacol       Date:  1981-05       Impact factor: 4.335

4.  A new class of angiotensin-converting enzyme inhibitors.

Authors:  A A Patchett; E Harris; E W Tristram; M J Wyvratt; M T Wu; D Taub; E R Peterson; T J Ikeler; J ten Broeke; L G Payne; D L Ondeyka; E D Thorsett; W J Greenlee; N S Lohr; R D Hoffsommer; H Joshua; W V Ruyle; J W Rothrock; S D Aster; A L Maycock; F M Robinson; R Hirschmann; C S Sweet; E H Ulm; D M Gross; T C Vassil; C A Stone
Journal:  Nature       Date:  1980-11-20       Impact factor: 49.962

5.  Isolation of membrane-bound renal kallikrein and kininase.

Authors:  P E Ward; C D Gedney; R M Dowben; E G Erdös
Journal:  Biochem J       Date:  1975-12       Impact factor: 3.857

6.  Angiotensin-converting enzyme: vascular endothelial localization.

Authors:  P R Caldwell; B C Seegal; K C Hsu; M Das; R L Soffer
Journal:  Science       Date:  1976-03-12       Impact factor: 47.728

7.  Increased glomerular filtration rate after converting-enzyme inhibition in essential hypertension.

Authors:  N K Hollenberg; S L Swartz; D R Passan; G H Williams
Journal:  N Engl J Med       Date:  1979-07-05       Impact factor: 91.245

8.  Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo.

Authors:  D M Gross; C S Sweet; E H Ulm; E P Backlund; A A Morris; D Weitz; D L Bohn; H C Wenger; T C Vassil; C A Stone
Journal:  J Pharmacol Exp Ther       Date:  1981-03       Impact factor: 4.030

9.  Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure.

Authors:  V J Dzau; W S Colucci; G H Williams; G Curfman; L Meggs; N K Hollenberg
Journal:  N Engl J Med       Date:  1980-06-19       Impact factor: 91.245

10.  Effects of captopril on blood pressure, electrolytes, and certain hormones in hypertension.

Authors:  L Guillevin; M D Lardoux; P Corvol
Journal:  Clin Pharmacol Ther       Date:  1981-06       Impact factor: 6.875

View more
  4 in total

1.  Evolution of diuretics and ACE inhibitors, their renal and antihypertensive actions--parallels and contrasts.

Authors:  A F Lant
Journal:  Br J Clin Pharmacol       Date:  1987       Impact factor: 4.335

2.  Lisinopril in hypertensive patients with and without renal failure.

Authors:  B A van Schaik; G G Geyskes; P Boer
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 3.  Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  P A Todd; R C Heel
Journal:  Drugs       Date:  1986-03       Impact factor: 9.546

4.  The effects of cilazapril alone and in combination with frusemide in healthy subjects.

Authors:  G D Johnston; A P Passmore
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.